二、监事会会议审议情况 1、审议通过了《关于公司监事会换届监事候选人提名的议案》； 股票代码：600216 股票简称：浙江医药 编号：2024-015 浙江医药股份有限公司第九届十四次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 浙江医药股份有限公司（以下简称"公司"或"本公司"）于 2024 年 5 月 27 日以通讯表决方式召开了第九届十四次监事会会议。本次会议的通知于 2024 年 5 月 20 日以电子邮件的方式发出。会议应到监事 5 人，实际参加监事 5 人， 符合《公司法》和《公司章程》的有关规定和要求。 2024 年 5 月 28 日 1 附件：第十届监事会监事候选人简历 李哲先生，1979年生，中共党员，北京大学金融专业硕士研究生。2002年7 月至2014年8月，历任中国高新投资集团公司高技术项目部职员、资产管理部项 目经理、投资团队高级投资经理；2014年8月至2017年12月，历任中国国投高新 产业投资有限公司投资开发部高级投资经理、健康团队高级投资经理；2 ...

浙江医药股份有限公司 独立董事提名人声明与承诺 提名人浙江医药股份有限公司董事会，现提名夏青为浙江医 药股份有限公司第十届董事会独立董事候选人，并已充分了解被 提名人职业、学历、职称、详细的工作经历、全部兼职、有无重 大失信等不良记录等情况。被提名人已同意出任浙江医药股份有 限公司第十届董事会独立董事候选人（参见该独立董事候选人声 明）。提名人认为，被提名人具备独立董事任职资格，与浙江医 药股份有限公司之间不存在任何影响其独立性的关系，具体声明 并承诺如下： 一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验， 并已经参加培训并取得证券交易所认可的相关培训证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （四）中共中央纪 ...

you. I'm not afraid of the dark. you Thank you. Oh, oh. ...

So, you. you so so so so ...

证券代码：600216 证券简称：浙江医药 公告编号：2024-012 浙江医药股份有限公司 关于第十届监事会职工监事选举结果的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 鉴于浙江医药股份有限公司（以下简称"公司"）第九届监事会任期即将届 满，根据《公司法》和《公司章程》的相关规定，经公司下属昌海生物分公司和 新昌制药厂召开第三届职工代表大会第三次会议和第九届职工代表大会第四次 会议选举通过，选举陈春峰同志、章鹏飞同志为公司第十届监事会职工监事，将 与公司 2023 年年度股东大会选举产生的三位监事共同组成公司第十届监事会， 任期三年。 附件：第十届监事会职工监事简历 特此公告。 浙江医药股份有限公司董事会 2024 年 5 月 17 日 附件：第十届监事会职工监事简历 陈春峰，男，1970 年生，中共党员，本科学历，高级经济师。1996 年 11 月至 2002 年 11 月任新昌制药厂 203 车间主任，2002 年 11 月至 2004 年 11 月任 新昌制药厂合一厂厂长，2004 年 11 月至 20 ...

Summary of Conference Call for Zhejiang Medicine Company Overview - **Company**: Zhejiang Medicine - **Industry**: Pharmaceutical and Nutritional Products Key Points Vitamin Market Dynamics - There has been a short-term fluctuation in the supply chain leading to increased inventory replenishment by distributors, which has positively impacted the prices and demand for vitamins in the short to medium term [1][6] - The overall economic environment is improving, but global demand for vitamins has not reached a level that justifies the current price increases [6] Innovation Drug Development - The progress of the innovative drug 788 is slower than expected, currently in the late stages of clinical trials for second-line treatment of HER2-positive breast cancer [2][7] - The company is facing regulatory challenges in obtaining production licenses for 788, which were not anticipated during the drug's design and clinical development phases [3][5] - The competitor DS8201 has already been approved, which may lead to a loss of market share for 788 due to its delayed commercialization [7][8] Financial Performance and Production Capacity - Vitamin E prices have increased, positively affecting profitability, with a continuous upward trend in earnings observed in the first quarter [11] - The company does not have immediate plans for capacity expansion due to regulatory constraints, but it aims to optimize production processes to reduce unit costs [11][12] - Capital expenditures are expected to be significant due to the need to transition production capacity from the old Xinjiang plant to other subsidiaries [12][14] Antibiotic Sales and Market Trends - Sales of Vancomycin and Daptomycin in overseas markets are still in a cultivation phase, contributing minimally to overall financial performance [16][17] - The demand for antibiotics has increased significantly in the domestic market, driven by rising antibiotic resistance, suggesting a sustained growth trend in this segment [20][21] Vitamin A Market Insights - The profitability of Vitamin A has been under pressure, with the company maintaining a breakeven point during the worst market conditions last year [23] - Future profitability predictions for Vitamin A are uncertain due to unclear supply dynamics and potential new entrants in the market [24] Production Capacity and Utilization - The overall capacity utilization for Vitamin A was satisfactory last year, but technical upgrades and maintenance may lead to a decrease in utilization rates this year [27] - The company plans to maintain production levels to ensure market share, despite potential short-term disruptions due to technical improvements [29] Nutritional Products and Revenue Goals - The company does not have specific revenue targets tied to market prices for its nutritional products, focusing instead on technological advancements and cost reductions [39] - New product introductions in the nutritional segment are planned but will not significantly change the product lineup in 2024 [40] Research and Development Investments - R&D investments for innovative drugs will continue, albeit at a reduced level, with a commitment to maintain over 100 million in funding for promising pipeline products [42] Future Outlook - The company is cautious about predicting the recovery of vitamin prices and overall market conditions, emphasizing the importance of internal operational improvements [37][39] This summary encapsulates the critical insights from the conference call, highlighting the company's current challenges and strategic directions in the pharmaceutical and nutritional sectors.

浙江医药股份有限公司 关于召开 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证券代码：600216 证券简称：浙江医药 公告编号：2024-011 （一）会议召开时间：2024 年 05 月 23 日下午 13:00-14:30 （二）会议召开地点：上证路演中心（网址：http://roadshow.sseinfo.com/） 会议召开时间：2024 年 05 月 23 日(星期四)下午 13:00-14:30 会议召开地点：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频播放和网络互动 （三）会议召开方式：上证路演中心视频播放和网络互动 三、 参加人员 公司副董事长、总裁吕春雷先生，独立董事裘益政先生，财务总监李齐融女 士，董事会秘书邵旻之先生。 投资者可于 2024 年 05 月 16 日(星期四)至 05 月 22 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏 ...

Investment Rating - The report maintains a "Buy" rating for Zhejiang Medicine (600216.SH) [11][16] Core Views - The vitamin market has shown signs of recovery, with significant performance improvement in Q1 2024. The company is focusing on R&D and the orderly progress of its pharmaceutical business [11][16] - The company's revenue for 2023 was 7.794 billion yuan, a decrease of 4% year-on-year, while the net profit attributable to shareholders was 430 million yuan, down 20% year-on-year. However, Q4 2023 saw a net profit of 130 million yuan, a 133% increase year-on-year [16] - In Q1 2024, the company achieved a revenue of 2.2 billion yuan, a 12% increase year-on-year, and a net profit of 110 million yuan, a 3% decrease year-on-year [16] Financial Performance Summary - The company's projected net profits for 2024, 2025, and 2026 are 484 million yuan (down 36%), 638 million yuan (down 29%), and 746 million yuan, respectively, with corresponding EPS of 0.50, 0.66, and 0.77 yuan [11][12] - Revenue is expected to grow from 8.623 billion yuan in 2024 to 10.599 billion yuan in 2026, with growth rates of 10.63%, 10.79%, and 10.95% [12] - The company's gross profit margin is projected to improve from 32.1% in 2024 to 35.5% in 2026 [12] R&D and Product Development - The company has increased its R&D investment, with R&D expenses reaching 860 million yuan in 2023, a 6% increase year-on-year [16] - New products are being developed, with several projects progressing through clinical trials and regulatory approvals, including various formulations and active pharmaceutical ingredients [16]

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------|-----------------------------|-------|--------|--------|----------|-------------------------------------------------------------------|-------------------------------|-------------|-------------|---------------|-------------| | 利润表（百万元） \n营业收入 8,116 7,794 8,623 9,553 10,599 | 2022 2023 2024E 2025E 2026E | | | | | 资产负债表（百万元） \n总资产 12,433 12,780 14,272 15,392 16,710 | 2022 2 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥7.79 billion, a decrease of 3.96% compared to ¥8.12 billion in 2022[38]. - Net profit attributable to shareholders for 2023 was approximately ¥429.64 million, down 20.37% from ¥539.57 million in 2022[38]. - The net profit after deducting non-recurring gains and losses was approximately ¥153.30 million, a significant decline of 70.19% from ¥514.24 million in 2022[38]. - The overall operating revenue decreased by 3.96% to ¥7,794,145,971.37, with operating costs decreasing by 0.91% to ¥5,269,878,689.98[95]. - The gross profit margin decreased by 2.26 percentage points to 32.56% compared to the previous year[98]. - The net profit attributable to the parent company's shareholders for 2023 is CNY 429,639,626.26, with the parent company's net profit at CNY 610,537,146.18[117]. - Basic earnings per share (EPS) for 2023 was 0.45 RMB, a decline of 19.64% from 0.56 RMB in 2022[46]. - The weighted average return on equity (ROE) decreased to 4.54% in 2023, down 1.45 percentage points from 5.99% in 2022[46]. Research and Development - Research and development expenses reached ¥860,072,434.06, representing 11.03% of total operating income, with no capitalized R&D expenditures[16]. - The company employed 866 R&D personnel, accounting for 13.91% of the total workforce, with 28 holding doctoral degrees and 167 holding master's degrees[27]. - Research and development expenses increased by 6.28% to ¥860,072,434.06, indicating a focus on innovation[95]. - R&D investment for the anti-Her2-ADC project was 12,272.09 million RMB, accounting for 1.57% of operating revenue, with a year-on-year decrease of 21.65%[135]. - R&D investment for the apple acid naphthomycin and injection project was 8,471.92 million RMB, accounting for 1.09% of operating revenue, with a year-on-year increase of 21.03%[135]. - R&D investment for new formulations was 1,721.60 million RMB, accounting for 0.22% of operating revenue, with a year-on-year decrease of 48.56%[135]. - R&D investment for raw material drug process and quality research was 2,013.19 million RMB, accounting for 0.26% of operating revenue, with a year-on-year increase of 22.20%[135]. - The company is actively engaged in research and development of new products and technologies to drive future growth[38]. Costs and Expenses - Total sales expenses for the reporting period amounted to ¥1,045,588,220.72, an increase of 17.41% compared to the previous year[15]. - Financial expenses decreased by 53.94% to -¥17,488,438.76, compared to -¥37,966,060.26 in the previous year[15]. - Management expenses increased by 3.04% to ¥445,186,095.66 from ¥432,066,700.89 year-on-year[15]. - Raw material costs for life nutrition products decreased by 19.54% to ¥1,319,115,043.90, accounting for 25.20% of total costs[28]. - Total manufacturing costs for pharmaceutical manufacturing products increased by 6.73% to ¥358,388,349.38, representing 6.85% of total costs[28]. - The total cost of medical commercial products was ¥2,143,849,737.29, which is a 5.58% increase compared to the previous year[30]. - The overall cost decreased by 0.51% to ¥5,235,009,431.80, with the previous year's total at ¥5,261,603,719.61[28]. - The cost of the apple acid nano antibiotic series increased by 149.65% to ¥113,100,788.46, representing 2.16% of total costs[30]. - The total cost for the other category rose by 12.60% to ¥452,746,783.50, accounting for 8.65% of total costs[30]. - The labor cost for pharmaceutical manufacturing products increased by 20.57% to ¥91,085,316.06, representing 1.74% of total costs[28]. Market and Sales - The top five customers contributed ¥115,868.49 million to sales, making up 14.87% of total annual sales, with no sales to related parties[21]. - Domestic sales revenue reached ¥5,601,204,363.19, a year-on-year increase of 4.75%, while foreign sales revenue was ¥2,160,829,972.03, a decrease of 20.72%[90]. - The sales of life nutrition products accounted for 41.99% of total revenue, totaling ¥327,264.20 million, a decrease of 14.80% year-on-year[94]. - The company is expanding its life nutrition products into "Belt and Road" countries to offset declining profitability in traditional markets[88]. - The company has established a relatively complete sales service network in North America, Europe, and South America for its pharmaceutical raw materials, primarily through self-export[75]. - The company has covered over 25,000 pharmacy terminals in China, achieving effective coverage in all regions except Tibet, with stable growth in online sales through platforms like Tmall and JD[138]. Cash Flow and Assets - The net cash flow from operating activities increased by 21.84% to approximately ¥634.31 million in 2023, compared to ¥520.60 million in 2022[38]. - The total assets at the end of 2023 were approximately ¥12.78 billion, reflecting a 2.79% increase from ¥12.43 billion at the end of 2022[38]. - The net assets attributable to shareholders increased by 4.00% to approximately ¥9.63 billion at the end of 2023, compared to ¥9.26 billion at the end of 2022[38]. - Cash received from operating activities increased by 70.46% to CNY 173,042,753.68 compared to the same period last year[104]. - Cash flow from the disposal of fixed assets surged by 2324.60% to CNY 174,476,876.29, primarily due to compensation received from the relocation of a vitamin factory[104]. - The company reported a significant increase in other receivables, rising by 255.05% to CNY 239,136,451.64[109]. Governance and Compliance - The company ensures compliance with information disclosure obligations, providing equal access to information for all shareholders[122]. - There are no significant differences between the company's governance practices and the regulations set by the China Securities Regulatory Commission[122]. - The company is committed to maintaining transparency and accuracy in its financial reporting and disclosures[122]. - The board of directors has designated a secretary and office to oversee information disclosure and shareholder inquiries[122]. - The company has plans to revise its Articles of Association and improve internal control systems as part of its governance strategy[122]. - The company continues to focus on compliance with legal and regulatory requirements in its governance practices[122]. - The audit committee approved the 2023 semi-annual report, confirming compliance with legal and regulatory requirements[150]. Strategic Initiatives - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming fiscal year[38]. - The company plans to continue expanding into Southeast Asian markets while consolidating its presence in Europe and the United States[63]. - The company is actively pursuing strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential mergers and acquisitions[127]. - The company has implemented new strategies to improve operational efficiency, aiming for a 5% reduction in production costs by the end of the fiscal year[127]. - The company has established various training programs, including management and compliance training, to enhance employee capabilities[158]. Environmental and Social Responsibility - The company invested 11,454.48 million yuan in environmental protection during the reporting period[194]. - The total wastewater discharge was 69.098 million tons, with COD emissions of 110.67 tons and ammonia nitrogen emissions of 3.18 tons[200]. - The company has established environmental protection mechanisms and is classified as a key pollutant discharge unit[200].